Ossium Health fetches $63m Series B

Ossium Health, a therapeutics company focused on using stem cell science to improve treatment for patients with blood and immune diseases, has closed $63 million in Series B funding.

Ossium Health, a therapeutics company focused on using stem cell science to improve treatment for patients with blood and immune diseases, has closed $63 million in Series B funding. General Catalyst and Vivo Capital led the round with participation from previous investors First Round Capital, Manta Ray Ventures, and XYZ Capital.

Source: Press Release